Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.56 |
| ▸ | F10 | P00742 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4410601 | 1.00 | F2 (0.56) | F2F10ALDH1A1TSHRPRSS1 | |
| SCHEMBL4405175 | 1.00 | F2 (0.56) | F2F10ALDH1A1TSHRPRSS1 | |
| SCHEMBL28008718 | 0.94 | F2 (0.58) | F2F10ALDH1A1TSHRPRSS1 | |
| SCHEMBL4572672 | 0.92 | F2 (0.52) | F2F10ALDH1A1TSHRPRSS1 | |
| SCHEMBL27974827 | 0.90 | F2 (0.46) | F2F10ALDH1A1TSHRPRSS1 | |
| SCHEMBL2719599 | 0.88 | F2 (0.61) | F2F10ALDH1A1TSHRPRSS1 | |
| SCHEMBL7143572 | 0.87 | F2 (0.58) | F2F10ALDH1A1TSHRPRSS1 | |
| SCHEMBL29012579 | 0.87 | NPC1 (0.52) | F2ALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL28267935 | 0.87 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9ASMN1; SMN2NAAA | |
| Hydrochloric Acid SCHEMBL7304105 | 0.86 | F2 (0.57) | F2F10ALDH1A1TSHRPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632888-B1 | A METHOD TO PREPARE BETA-FUNCTIONALIZED ALIPHATIC ESTERS | COGNIS IP MAN GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| US-8877958-B2 | Method to prepare beta-functionalized aliphatic esters | COGNIS IP MANAGEMENT GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-8877958-B2 | Method to prepare beta-functionalized aliphatic esters | COGNIS IP MANAGEMENT GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20130225852-A1 | Method To Prepare beta-Functionalized Aliphatic Esters | COGNIS IP MANAGEMENT GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225852-A1 | Method To Prepare beta-Functionalized Aliphatic Esters | COGNIS IP MANAGEMENT GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225852-A1 | Method To Prepare beta-Functionalized Aliphatic Esters | CYP8B1, EBP, DBH | F2 3005/4885F10 2760/4885ALDH1A1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.